Glioblastoma Treatment Options: Surgery, Therapy, and Mental Health Support

Glioblastoma is a rare, aggressive brain cancer treated primarily through a multidisciplinary approach involving surgical resection, radiation therapy, and chemotherapy. According to medical specialists, standard interventions are carefully combined with emerging technologies like Tumor Treating Fields to balance therapeutic efficacy with patient quality of life.

In Plain English: The Clinical Takeaway

• Stupp Protocol: The clinical gold standard combining six weeks of radiation therapy alongside oral chemotherapy to target microscopic cancer cells left behind after surgery.
• Molecular Biomarkers: Genetic testing on removed tumor tissue helps doctors tailor specific therapeutic regimens.
• Tumor Treating Fields (TTFields): A non-invasive therapy using portable electrical patches worn on the scalp to disrupt rapid cancer cell division.

Surgical Interventions and Molecular Diagnostics

Treatment for glioblastoma typically initiates with surgery to debulk the mass and relieve intracranial pressure. When tumors infiltrate critical functional regions, neurosurgeons may perform an awake craniotomy, allowing continuous patient monitoring of language and motor functions. Because glioblastomas feature diffuse, finger-like projections that invade surrounding parenchyma, complete macroscopic removal remains exceptionally difficult, necessitating adjuvant systemic therapies.

Following resection, tissue samples undergo rigorous pathology. If anatomical location or underlying comorbidities preclude open surgery, a biopsy is performed to confirm histopathological diagnosis safely.

Radiation Oncology and Standard Chemotherapy

To address residual neoplastic cells, postoperative care standardly integrates radiation therapy. The prevailing paradigm remains the Stupp protocol, which administers localized energy beams concurrently with oral temozolomide (TMZ) chemotherapy over a six-week period. Radiation oncologists deploy various techniques depending on spatial constraints, including Intensity-Modulated Radiation Therapy (IMRT) for precision targeting and Stereotactic Radiosurgery for small, well-defined lesions. While external beam radiation remains foundational, side effects frequently involve fatigue, alopecia, and cognitive changes.

Complementing radiation, systemic agents like temozolomide, carmustine, and lomustine act to compromise DNA replication within rapidly dividing cancer cells. For recurrent disease presentations, clinicians may administer intravenous therapies or utilize targeted options such as bevacizumab, a monoclonal antibody designed to inhibit angiogenesis—the formation of new blood vessels supplying the tumor.

Bioelectric Modalities and Supportive Care Integration

Beyond traditional pharmacotherapy, Tumor Treating Fields (TTFields) offer a distinct mechanism of action. By delivering low-intensity, alternating electrical fields via scalp electrode arrays, the portable device disrupts mitotic spindle formation during cell division. Integrated early within care pathways, palliative teams address symptom management, cognitive changes, and emotional distress without replacing disease-directed oncological care.

Photo: abta.org

Standard Modalities in Glioblastoma Management

Treatment Modality	Primary Mechanism of Action	Common Clinical Application
Surgical Resection	Mechanical debulking and tissue biopsy acquisition	Initial primary intervention
Stupp Protocol	Concurrent focal radiation and oral temozolomide (TMZ)	Standard newly diagnosed care
TTFields	Disruption of cellular mitosis via alternating electrical fields	Maintenance therapy post-chemoradiation
Bevacizumab	Inhibition of vascular endothelial growth factor (VEGF)	Recurrent glioblastoma management

Contraindications & When to Consult a Doctor

References

• American Brain Tumor Association. Glioblastoma (GBM) Overview and Treatment Guidelines.
• National Cancer Institute. Adult Brain Tumors Treatment (PDQ®)–Health Professional Version.
• World Health Organization. Classification of Tumours of the Central Nervous System.